Price movement over the last 24 hours
REX AI Equity Premium Income ETF vs Tilray Brands Inc — how do they compare? REX AI Equity Premium Income ETF trades at $36.06, while Tilray Brands Inc trades at $4.33 (market cap $532.10M). The key difference: REX AI Equity Premium Income ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| AIPI | TLRY | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $21.00 |
52-Week Low | $32.45 | $4.31 |
Market Cap | — | $532.10M |
Enterprise Value | — | $629.24M |
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.10, up 1.87% with neutral technical signals. The ETF maintains a high weekly dividend distribution strategy, recently transitioning to weekly payouts. Technical analysis shows mixed signals with bullish moving averages but neutral oscillators, trading near key support at $37. Recent news highlights concerns about NAV erosion risk despite the attractive yield structure.
The outlook remains cautious due to structural limitations in the option-writing strategy that caps upside potential. While the ~34.8% yield appears attractive, sustainability depends heavily on AI market momentum. Investors face NAV erosion risk if technology sector performance falters, requiring careful monitoring of the fund's premium income strategy effectiveness.
TLRY trades at $4.38, down 5.19% today, reflecting ongoing investor concerns about profitability despite revenue growth to $821 million in 2025. The stock shows bearish technical signals with key support at $4 and resistance at $5. Recent acquisitions and medical cannabis expansion provide growth avenues, but negative net income margins and cash flow challenges persist. Analyst consensus remains cautious with 65% hold ratings.
TLRY presents a high-risk opportunity with potential upside from strategic acquisitions and market expansion, but significant challenges include persistent losses, negative cash flow, and regulatory uncertainties. The stock's low P/S (0.54) and P/B (0.35) ratios suggest undervaluation, but profitability remains the critical hurdle for sustainable growth.
Trailing returns across standard periods
Latest headlines on both assets
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →